You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIndapamide
Accession NumberDB00808  (APRD01031)
TypeSmall Molecule
GroupsApproved
DescriptionA benzamide-sulfonamide-indole. It is called a thiazide-like diuretic but structure is different enough (lacking the thiazo-ring) so it is not clear that the mechanism is comparable. [PubChem]
Structure
Thumb
Synonyms
Indapamid
Indapamida
Indapamide
Indapamidum
Metindamide
External Identifiers
  • RHC 2555
  • S 1520
  • SE 1520
  • USV 2555
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-indapamide Tablets 1.25mgtablet1.25 mgoralDominion Pharmacal1999-09-15Not applicableCanada
Dom-indapamide Tablets 2.5mgtablet2.5 mgoralDominion Pharmacal1999-09-15Not applicableCanada
Indapamidetablet1.25 mgoralSanis Health Inc2015-10-14Not applicableCanada
Indapamidetablet2.5 mgoralSanis Health IncNot applicableNot applicableCanada
Indapamidetablet2.5 mgoralSanis Health Inc2015-10-14Not applicableCanada
Indapamide Hemihydrate 1.25mg - Tabtablet1.25 mgoralProval Pharma Division Of Servier Canada Inc1997-08-142012-02-13Canada
Indapamide Hemihydrate Tab 2.5mgtablet2.5 mgoralProval Pharma Division Of Servier Canada Inc1995-12-312012-02-13Canada
Indapamide-2.5tablet2.5 mgoralPro Doc Limitee1997-04-302008-07-04Canada
Jamp-indapamidetablet1.25 mgoralJamp Pharma Corporation2011-10-17Not applicableCanada
Jamp-indapamidetablet2.5 mgoralJamp Pharma Corporation2011-10-17Not applicableCanada
Lozidetablet1.25 mgoralServier Canada Inc1995-12-31Not applicableCanada
Lozidetablet2.5 mgoralServier Canada Inc1982-12-31Not applicableCanada
Mylan-indapamidetablet2.5 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-indapamidetablet1.25 mgoralMylan Pharmaceuticals Ulc1999-05-10Not applicableCanada
Ntp-indapamidetablet2.5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-indapamidetablet1.25 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-indapamide - Tab 2.5mgtablet2.5 mgoralNu Pharm Inc1996-08-292012-09-04Canada
PHL-indapamidetablet2.5 mgoralPharmel Inc2002-05-28Not applicableCanada
PHL-indapamidetablet1.25 mgoralPharmel Inc2002-05-28Not applicableCanada
PMS-indapamidetablet1.25 mgoralPharmascience Inc1999-02-18Not applicableCanada
PMS-indapamidetablet2.5 mgoralPharmascience Inc1999-02-18Not applicableCanada
Pro-indapamidetablet2.5 mgoralPro Doc Limitee2008-07-04Not applicableCanada
Pro-indapamidetablet1.25 mgoralPro Doc Limitee2008-07-04Not applicableCanada
Riva-indapamide 1.25tablet1.25 mgoralLaboratoire Riva Inc2003-03-11Not applicableCanada
Riva-indapamide 2.5 mgtablet2.5 mgoralLaboratoire Riva Inc2000-05-10Not applicableCanada
Teva-indapamidetablet2.5 mgoralTeva Canada Limited1997-05-04Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-indapamide 1.25 Mg Tabletstablet1.25 mgoralApotex Inc2002-11-08Not applicableCanada
Apo-indapamide 2.5mg Tabletstablet2.5 mgoralApotex Inc1996-10-02Not applicableCanada
Indapamidetablet, film coated2.5 mg/1oralMylan Institutional Inc.1996-05-01Not applicableUs
Indapamidetablet, film coated2.5 mg/1oralActavis Elizabeth LLC2007-01-02Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralRebel Distributors Corp2010-01-18Not applicableUs
Indapamidetablet, film coated2.5 mg/1oralbryant ranch prepack2007-01-02Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralActavis Elizabeth LLC2007-01-02Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralAv Kare, Inc.2016-02-09Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-07-12Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralCarilion Materials Management1997-03-26Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralMylan Pharmaceuticals Inc.1997-03-26Not applicableUs
Indapamidetablet, film coated2.5 mg/1oralAv Kare, Inc.2016-02-09Not applicableUs
Indapamidetablet2.5 mg/1oralREMEDYREPACK INC.2010-09-16Not applicableUs
Indapamidetablet, film coated2.5 mg/1oralMylan Pharmaceuticals Inc.1996-03-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArifonServier
BajatenMerck
FludexServier
IndamolTeofarma
IpamixVisufarma
LozideServier
Lozolsanofi-aventis
NatrilixServier
NatrixKyoto Yakuhin
NoranatSandoz
TandixAzevedos
TertensifServier
VeroxilBaldacci
Brand mixtures
NameLabellerIngredients
Arcosyl PlusServier Canada Inc
Arcosyl Plus LdServier Canada Inc
Coversyl PlusServier Canada Inc
Coversyl Plus HdServier Canada Inc
Coversyl Plus LdServier Canada Inc
SaltsNot Available
Categories
UNIIF089I0511L
CAS number26807-65-8
WeightAverage: 365.835
Monoisotopic: 365.06008979
Chemical FormulaC16H16ClN3O3S
InChI KeyInChIKey=NDDAHWYSQHTHNT-UHFFFAOYSA-N
InChI
InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
IUPAC Name
4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide
SMILES
CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • 4-halobenzoic acid or derivatives
  • Benzenesulfonamide
  • Indole or derivatives
  • Benzoic acid or derivatives
  • Benzamide
  • Benzoyl
  • Halobenzene
  • Chlorobenzene
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.
PharmacodynamicsIndapamide is an antihypertensive and a diuretic. It contains both a polar sulfamoyl chlorobenzamide moiety and a lipid- soluble methylindoline moiety. Indapamide bears a structural similarity to the triazide diuretics which are known to decrease vascular smooth muscle reactivity. However, it differs chemically from the thiazides in that it does not possess the thiazide ring system and contains only one sulfonamide group. Indapamide appears to cause vasodilation, probably by inhibiting the passage of calcium and other ions (sodium, potassium) across membranes. This same effect may cause hypokalcemia in susceptible individuals. Indapamide has also been shown to cause uterine myometrial relaxation in experimental animals. Overall, indapamide has an extra-renal antihypertensive action resulting in a decrease in vascular hyperreactivity and a reduction in total peripheral and arteriolar resistance.
Mechanism of actionIndapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2.
Related Articles
AbsorptionRapidly absorbed from gastrointestinal tract.
Volume of distributionNot Available
Protein binding71-79%
Metabolism

Primarily hepatic. Indapamide is an extensively metabolized drug with only about 7+ACU- of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration.

SubstrateEnzymesProduct
Indapamide
Indapamide metabolite M5Details
Indapamide metabolite M5
Indapamide metabolite M4Details
Indapamide metabolite M4
Not Available
Indapamide metabolite M2Details
Indapamide
Indapamide metabolite M1Details
Indapamide metabolite M1
Indapamide metabolite M3Details
Indapamide metabolite M3
Indapamide metabolite M2Details
Indapamide
Indapamide epoxide intermediateDetails
Indapamide epoxide intermediate
Indapamide metabolite M6Details
Route of eliminationIndapamide is an extensively metabolized drug, with only about 7% of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration.
Half life14 hours (biphasic)
ClearanceNot Available
ToxicitySide effects include electrolyte imbalance (potassium or salt depletion due to too much fluid loss), nausea, stomach disorders, vomiting, weakness
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Indapamide Action PathwayDrug actionSMP00110
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8868
Caco-2 permeable-0.5529
P-glycoprotein substrateNon-substrate0.6859
P-glycoprotein inhibitor INon-inhibitor0.9158
P-glycoprotein inhibitor IINon-inhibitor0.9179
Renal organic cation transporterNon-inhibitor0.8575
CYP450 2C9 substrateNon-substrate0.5265
CYP450 2D6 substrateNon-substrate0.7924
CYP450 3A4 substrateNon-substrate0.519
CYP450 1A2 substrateInhibitor0.582
CYP450 2C9 inhibitorNon-inhibitor0.5775
CYP450 2D6 inhibitorNon-inhibitor0.8151
CYP450 2C19 inhibitorNon-inhibitor0.6572
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7471
Ames testNon AMES toxic0.6869
CarcinogenicityNon-carcinogens0.7674
BiodegradationNot ready biodegradable0.9862
Rat acute toxicity2.0823 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.986
hERG inhibition (predictor II)Non-inhibitor0.8804
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Cadista pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral2.5 mg/1
Tablet, film coatedoral1.25 mg/1
Tablet, film coatedoral2.5 mg/1
Tabletoral2.5 mg
Tabletoral1.25 mg
Prices
Unit descriptionCostUnit
Indapamide 2.5 mg tablet0.85USD tablet
Indapamide 1.25 mg tablet0.69USD tablet
Lozide 2.5 mg Tablet0.55USD tablet
Apo-Indapamide 2.5 mg Tablet0.31USD tablet
Mylan-Indapamide 2.5 mg Tablet0.31USD tablet
Novo-Indapamide 2.5 mg Tablet0.31USD tablet
Nu-Indapamide 2.5 mg Tablet0.31USD tablet
Pms-Indapamide 2.5 mg Tablet0.31USD tablet
Apo-Indapamide 1.25 mg Tablet0.2USD tablet
Mylan-Indapamide 1.25 mg Tablet0.2USD tablet
Pms-Indapamide 1.25 mg Tablet0.2USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point160-162U.S.Patent 3,565,911.
water solubility75 mg/LNot Available
logP2.2Not Available
pKa8.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0342 mg/mLALOGPS
logP2.52ALOGPS
logP2.64ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)8.85ChemAxon
pKa (Strongest Basic)0.097ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.5 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity103.31 m3·mol-1ChemAxon
Polarizability36.34 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Chunyi Yeh, Yi-Lung Wang, Ya-Sheng Yang, Ya-Ching Chang Chein, “Oral sustained-release pharmaceutical composition of indapamide, production and use thereof.” U.S. Patent US20060182803, issued August 17, 2006.

US20060182803
General References
  1. Dong DL, Wang QH, Yue P, Jiao JD, Gu RM, Yang BF: Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84. Epub 2006 Mar 2. [PubMed:16556441 ]
External Links
ATC CodesC03BA11C09BX01
AHFS Codes
  • 40:28.24
PDB EntriesNot Available
FDA labelDownload (322 KB)
MSDSDownload (72.7 KB)
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Indapamide.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Indapamide.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Indapamide.
AcebutololIndapamide may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Acetazolamide.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Indapamide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigitoxin.
Acetylsalicylic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Acetylsalicylic acid.
AclidiniumThe serum concentration of Indapamide can be increased when it is combined with Aclidinium.
AdapaleneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Adapalene.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Indapamide.
AlclometasoneAlclometasone may increase the hypokalemic activities of Indapamide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Indapamide.
AldosteroneAldosterone may increase the hypokalemic activities of Indapamide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Indapamide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Indapamide.
AliskirenIndapamide may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Indapamide.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Indapamide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Indapamide.
AlprenololIndapamide may increase the hypotensive activities of Alprenolol.
AmbrisentanIndapamide may increase the hypotensive activities of Ambrisentan.
AmcinonideAmcinonide may increase the hypokalemic activities of Indapamide.
AmifostineIndapamide may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Indapamide.
AmiodaroneThe metabolism of Indapamide can be decreased when combined with Amiodarone.
AmiodaroneIndapamide may increase the QTc-prolonging activities of Amiodarone.
AmlodipineAmlodipine may increase the hypotensive activities of Indapamide.
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Indapamide.
AmoxapineAmoxapine may increase the hyponatremic activities of Indapamide.
Amyl NitriteThe risk or severity of adverse effects can be increased when Indapamide is combined with Amyl Nitrite.
AnagrelideIndapamide may increase the QTc-prolonging activities of Anagrelide.
Anisotropine MethylbromideThe serum concentration of Indapamide can be increased when it is combined with Anisotropine Methylbromide.
AntipyrineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Indapamide is combined with Apraclonidine.
ApremilastThe therapeutic efficacy of Indapamide can be decreased when used in combination with Apremilast.
AprepitantThe serum concentration of Indapamide can be increased when it is combined with Aprepitant.
ArbutamineArbutamine may increase the hypokalemic activities of Indapamide.
ArformoterolArformoterol may increase the hypokalemic activities of Indapamide.
AripiprazoleAripiprazole may increase the hypotensive activities of Indapamide.
Arsenic trioxideIndapamide may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherIndapamide may increase the QTc-prolonging activities of Artemether.
AsenapineIndapamide may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe metabolism of Indapamide can be decreased when combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Indapamide.
AtomoxetineThe metabolism of Indapamide can be decreased when combined with Atomoxetine.
Atracurium besylateThe serum concentration of Indapamide can be increased when it is combined with Atracurium besylate.
AtropineThe serum concentration of Indapamide can be increased when it is combined with Atropine.
AzapropazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Indapamide is combined with Azilsartan medoxomil.
AzithromycinIndapamide may increase the QTc-prolonging activities of Azithromycin.
BalsalazideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Balsalazide.
BambuterolBambuterol may increase the hypokalemic activities of Indapamide.
BarbitalBarbital may increase the orthostatic hypotensive activities of Indapamide.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Indapamide.
BedaquilineIndapamide may increase the QTc-prolonging activities of Bedaquiline.
BenactyzineThe serum concentration of Indapamide can be increased when it is combined with Benactyzine.
BenazeprilBenazepril may increase the hypotensive activities of Indapamide.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Indapamide.
BenmoxinBenmoxin may increase the hypotensive activities of Indapamide.
BenoxaprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Benoxaprofen.
BenzatropineThe serum concentration of Indapamide can be increased when it is combined with Benzatropine.
BepridilIndapamide may increase the hypotensive activities of Bepridil.
BetamethasoneBetamethasone may increase the hypokalemic activities of Indapamide.
BetaxololBetaxolol may increase the hypotensive activities of Indapamide.
BethanidineBethanidine may increase the hypotensive activities of Indapamide.
BexaroteneThe serum concentration of Indapamide can be decreased when it is combined with Bexarotene.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Indapamide.
BimatoprostIndapamide may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Indapamide can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the hypotensive activities of Indapamide.
BoceprevirThe metabolism of Indapamide can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Indapamide can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Indapamide can be decreased when it is combined with Bosentan.
BosentanIndapamide may increase the hypotensive activities of Bosentan.
BretyliumIndapamide may increase the hypotensive activities of Bretylium.
BrimonidineIndapamide may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Indapamide.
BromfenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bromfenac.
BudesonideBudesonide may increase the hypokalemic activities of Indapamide.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Indapamide.
BumetanideThe risk or severity of adverse effects can be increased when Indapamide is combined with Bumetanide.
BupranololIndapamide may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Indapamide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Indapamide.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Indapamide.
CandesartanCandesartan may increase the hypotensive activities of Indapamide.
CandoxatrilCandoxatril may increase the hypotensive activities of Indapamide.
CaptoprilIndapamide may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Indapamide is combined with Carbamazepine.
CarbamazepineThe metabolism of Indapamide can be increased when combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Indapamide.
CaroxazoneCaroxazone may increase the hypotensive activities of Indapamide.
CarprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Indapamide.
CarvedilolIndapamide may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Indapamide.
CelecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Celecoxib.
CeliprololIndapamide may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Indapamide can be increased when it is combined with Ceritinib.
CeritinibIndapamide may increase the QTc-prolonging activities of Ceritinib.
ChloroquineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Chloroquine.
ChloroquineIndapamide may increase the QTc-prolonging activities of Chloroquine.
ChlorothiazideIndapamide may increase the hypotensive activities of Chlorothiazide.
ChlorphenoxamineThe serum concentration of Indapamide can be increased when it is combined with Chlorphenoxamine.
ChlorpromazineIndapamide may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Indapamide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Indapamide.
CholestyramineCholestyramine can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Indapamide.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Indapamide.
CilazaprilIndapamide may increase the hypotensive activities of Cilazapril.
CiprofloxacinIndapamide may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideIndapamide may increase the QTc-prolonging activities of Cisapride.
CitalopramCitalopram may increase the hyponatremic activities of Indapamide.
CitalopramIndapamide may increase the QTc-prolonging activities of Citalopram.
ClarithromycinIndapamide may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Indapamide can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Indapamide can be decreased when combined with Clemastine.
ClenbuterolClenbuterol may increase the hypokalemic activities of Indapamide.
ClevidipineThe risk or severity of adverse effects can be increased when Indapamide is combined with Clevidipine.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Indapamide.
ClocortoloneClocortolone may increase the hypokalemic activities of Indapamide.
ClomipramineClomipramine may increase the hyponatremic activities of Indapamide.
ClonidineClonidine may increase the hypotensive activities of Indapamide.
ClonixinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Clonixin.
ClotrimazoleThe metabolism of Indapamide can be decreased when combined with Clotrimazole.
ClozapineIndapamide may increase the QTc-prolonging activities of Clozapine.
CobicistatThe metabolism of Indapamide can be decreased when combined with Cobicistat.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Indapamide.
ColesevelamColesevelam can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Indapamide can be increased when it is combined with Conivaptan.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Indapamide.
CrizotinibIndapamide may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Indapamide can be decreased when combined with Crizotinib.
CryptenamineCryptenamine may increase the hypotensive activities of Indapamide.
CyclopentolateThe serum concentration of Indapamide can be increased when it is combined with Cyclopentolate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Cyclophosphamide.
CyclosporineThe metabolism of Indapamide can be decreased when combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Indapamide.
D-LimoneneThe therapeutic efficacy of Indapamide can be decreased when used in combination with D-Limonene.
DabrafenibThe serum concentration of Indapamide can be decreased when it is combined with Dabrafenib.
DapagliflozinThe risk or severity of adverse effects can be increased when Indapamide is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the hyponatremic activities of Indapamide.
DarifenacinThe serum concentration of Indapamide can be increased when it is combined with Darifenacin.
DarunavirThe metabolism of Indapamide can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Indapamide can be increased when it is combined with Dasatinib.
DebrisoquinIndapamide may increase the hypotensive activities of Debrisoquin.
DeferasiroxThe serum concentration of Indapamide can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Indapamide.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Indapamide.
DelavirdineThe metabolism of Indapamide can be decreased when combined with Delavirdine.
DeserpidineIndapamide may increase the hypotensive activities of Deserpidine.
DeslanosideThe risk or severity of adverse effects can be increased when Indapamide is combined with Deslanoside.
DesloratadineThe serum concentration of Indapamide can be increased when it is combined with Desloratadine.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Indapamide.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Indapamide.
DexamethasoneDexamethasone may increase the hypokalemic activities of Indapamide.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Indapamide.
DexetimideThe serum concentration of Indapamide can be increased when it is combined with Dexetimide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indapamide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indapamide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Indapamide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Indapamide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Indapamide.
DiazoxideDiazoxide may increase the hypotensive activities of Indapamide.
DiazoxideThe risk or severity of adverse effects can be increased when Indapamide is combined with Diazoxide.
DiclofenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Diclofenamide.
DicyclomineThe serum concentration of Indapamide can be increased when it is combined with Dicyclomine.
DiflorasoneDiflorasone may increase the hypokalemic activities of Indapamide.
DiflunisalThe therapeutic efficacy of Indapamide can be decreased when used in combination with Diflunisal.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Indapamide.
DifluprednateDifluprednate may increase the hypokalemic activities of Indapamide.
DigitoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Indapamide.
DihydroergotamineThe metabolism of Indapamide can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Indapamide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Indapamide.
DiltiazemDiltiazem may increase the hypotensive activities of Indapamide.
DinutuximabThe risk or severity of adverse effects can be increased when Indapamide is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Indapamide.
DipivefrinDipivefrin may increase the hypokalemic activities of Indapamide.
DipyridamoleThe risk or severity of adverse effects can be increased when Indapamide is combined with Dipyridamole.
DisopyramideIndapamide may increase the QTc-prolonging activities of Disopyramide.
DobutamineDobutamine may increase the hypokalemic activities of Indapamide.
DofetilideIndapamide may increase the QTc-prolonging activities of Dofetilide.
DolasetronIndapamide may increase the QTc-prolonging activities of Dolasetron.
DomperidoneIndapamide may increase the QTc-prolonging activities of Domperidone.
DorzolamideIndapamide may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Indapamide.
DoxycyclineThe metabolism of Indapamide can be decreased when combined with Doxycycline.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Indapamide.
DronedaroneThe metabolism of Indapamide can be decreased when combined with Dronedarone.
DronedaroneIndapamide may increase the QTc-prolonging activities of Dronedarone.
DroperidolIndapamide may increase the QTc-prolonging activities of Droperidol.
DroxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Droxicam.
DroxidopaDroxidopa may increase the hypokalemic activities of Indapamide.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Indapamide.
DuloxetineIndapamide may increase the orthostatic hypotensive activities of Duloxetine.
EfavirenzThe serum concentration of Indapamide can be decreased when it is combined with Efavirenz.
EfonidipineIndapamide may increase the hypotensive activities of Efonidipine.
EliglustatIndapamide may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Indapamide.
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Indapamide.
EnalaprilEnalapril may increase the hypotensive activities of Indapamide.
EnalaprilatIndapamide may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Indapamide can be decreased when it is combined with Enzalutamide.
EphedraEphedra may increase the hypokalemic activities of Indapamide.
EpinephrineEpinephrine may increase the hypokalemic activities of Indapamide.
EpirizoleThe therapeutic efficacy of Indapamide can be decreased when used in combination with Epirizole.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Indapamide.
EpoprostenolIndapamide may increase the hypotensive activities of Epoprostenol.
EprosartanIndapamide may increase the hypotensive activities of Eprosartan.
EquileninEquilenin may increase the hypokalemic activities of Indapamide.
EquilinEquilin may increase the hypokalemic activities of Indapamide.
ErythromycinIndapamide may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Indapamide can be decreased when combined with Erythromycin.
EscitalopramEscitalopram may increase the hyponatremic activities of Indapamide.
EscitalopramIndapamide may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Indapamide can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Indapamide.
EstroneEstrone may increase the hypokalemic activities of Indapamide.
Etacrynic acidThe risk or severity of adverse effects can be increased when Indapamide is combined with Etacrynic acid.
EtanerceptThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etanercept.
EthanolEthanol may increase the orthostatic hypotensive activities of Indapamide.
EthopropazineThe serum concentration of Indapamide can be increased when it is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Indapamide.
EtodolacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etofenamate.
EtoperidoneEtoperidone may increase the hyponatremic activities of Indapamide.
EtoricoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Indapamide.
EtravirineThe serum concentration of Indapamide can be decreased when it is combined with Etravirine.
Evening primrose oilThe therapeutic efficacy of Indapamide can be decreased when used in combination with Evening primrose oil.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Indapamide.
exisulindThe therapeutic efficacy of Indapamide can be decreased when used in combination with exisulind.
FelodipineIndapamide may increase the hypotensive activities of Felodipine.
FenbufenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fenbufen.
FenfluramineFenfluramine may increase the hyponatremic activities of Indapamide.
FenoldopamFenoldopam may increase the hypotensive activities of Indapamide.
FenoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may increase the hypokalemic activities of Indapamide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Indapamide.
FesoterodineThe serum concentration of Indapamide can be increased when it is combined with Fesoterodine.
FlecainideIndapamide may increase the QTc-prolonging activities of Flecainide.
FloctafenineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Floctafenine.
FluconazoleThe metabolism of Indapamide can be decreased when combined with Fluconazole.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Indapamide.
FlumethasoneFlumethasone may increase the hypokalemic activities of Indapamide.
FlunisolideFlunisolide may increase the hypokalemic activities of Indapamide.
FlunixinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Flunixin.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Indapamide.
FluocinonideFluocinonide may increase the hypokalemic activities of Indapamide.
FluocortoloneFluocortolone may increase the hypokalemic activities of Indapamide.
FluorometholoneFluorometholone may increase the hypokalemic activities of Indapamide.
FluoxetineFluoxetine may increase the hyponatremic activities of Indapamide.
FluoxetineIndapamide may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolIndapamide may increase the QTc-prolonging activities of Flupentixol.
FluprednideneFluprednidene may increase the hypokalemic activities of Indapamide.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Indapamide.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Indapamide.
FlurbiprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Flurbiprofen.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Indapamide.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Indapamide.
FluvoxamineFluvoxamine may increase the hyponatremic activities of Indapamide.
FormoterolFormoterol may increase the hypokalemic activities of Indapamide.
FosamprenavirThe metabolism of Indapamide can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Indapamide can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Indapamide.
FosphenytoinThe metabolism of Indapamide can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Indapamide.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Indapamide.
Fusidic AcidThe serum concentration of Indapamide can be increased when it is combined with Fusidic Acid.
Gadobenic acidIndapamide may increase the QTc-prolonging activities of Gadobenic acid.
Gallamine TriethiodideThe serum concentration of Indapamide can be increased when it is combined with Gallamine Triethiodide.
GemifloxacinIndapamide may increase the QTc-prolonging activities of Gemifloxacin.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Indapamide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Indapamide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Indapamide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Indapamide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Indapamide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Indapamide.
GlycopyrroniumThe serum concentration of Indapamide can be increased when it is combined with Glycopyrronium.
GoserelinIndapamide may increase the QTc-prolonging activities of Goserelin.
GranisetronIndapamide may increase the QTc-prolonging activities of Granisetron.
GuanabenzGuanabenz may increase the hypotensive activities of Indapamide.
GuanadrelGuanadrel may increase the hypotensive activities of Indapamide.
GuanethidineIndapamide may increase the hypotensive activities of Guanethidine.
GuanfacineIndapamide may increase the hypotensive activities of Guanfacine.
HaloperidolIndapamide may increase the QTc-prolonging activities of Haloperidol.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Indapamide.
HexamethoniumIndapamide may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Indapamide.
HMPL-004The therapeutic efficacy of Indapamide can be decreased when used in combination with HMPL-004.
HomatropineThe serum concentration of Indapamide can be increased when it is combined with Homatropine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Indapamide.
HydralazineIndapamide may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideIndapamide may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Indapamide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Indapamide.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Indapamide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Indapamide.
HyoscyamineThe serum concentration of Indapamide can be increased when it is combined with Hyoscyamine.
IbuprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuproxam.
IbutilideIndapamide may increase the QTc-prolonging activities of Ibutilide.
IcatibantThe therapeutic efficacy of Indapamide can be decreased when used in combination with Icatibant.
IdelalisibThe serum concentration of Indapamide can be increased when it is combined with Idelalisib.
IloperidoneIndapamide may increase the QTc-prolonging activities of Iloperidone.
IloprostIloprost may increase the hypotensive activities of Indapamide.
ImatinibThe metabolism of Indapamide can be decreased when combined with Imatinib.
IndacaterolIndacaterol may increase the hypokalemic activities of Indapamide.
IndalpineIndalpine may increase the hyponatremic activities of Indapamide.
IndenololIndapamide may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Indapamide can be decreased when combined with Indinavir.
IndomethacinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indoprofen.
IndoraminIndapamide may increase the hypotensive activities of Indoramin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Indapamide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Indapamide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Indapamide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Indapamide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Indapamide.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Indapamide.
Ipratropium bromideThe serum concentration of Indapamide can be increased when it is combined with Ipratropium bromide.
IproclozideIproclozide may increase the hypotensive activities of Indapamide.
IproniazidIproniazid may increase the hypotensive activities of Indapamide.
IrbesartanIndapamide may increase the hypotensive activities of Irbesartan.
IsavuconazoniumThe metabolism of Indapamide can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Indapamide.
IsoetarineIsoetarine may increase the hypokalemic activities of Indapamide.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Indapamide.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Mononitrate.
IsoxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Indapamide is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Indapamide.
ItraconazoleThe metabolism of Indapamide can be decreased when combined with Itraconazole.
IvabradineIndapamide may increase the arrhythmogenic activities of Ivabradine.
IvacaftorThe serum concentration of Indapamide can be increased when it is combined with Ivacaftor.
KebuzoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Kebuzone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Indapamide.
KetoconazoleThe metabolism of Indapamide can be decreased when combined with Ketoconazole.
KetoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Indapamide.
LacidipineIndapamide may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Indapamide.
LeflunomideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Leflunomide.
LenvatinibIndapamide may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineLercanidipine may increase the hypotensive activities of Indapamide.
LeuprolideIndapamide may increase the QTc-prolonging activities of Leuprolide.
LevobunololThe risk or severity of adverse effects can be increased when Indapamide is combined with Levobunolol.
LevodopaIndapamide may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinIndapamide may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Indapamide.
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Indapamide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Indapamide.
LicoriceLicorice may increase the hypokalemic activities of Indapamide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Indapamide.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Indapamide.
LisinoprilLisinopril may increase the hypotensive activities of Indapamide.
LithiumIndapamide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Indapamide.
LofexidineIndapamide may increase the hypotensive activities of Lofexidine.
LopinavirThe metabolism of Indapamide can be decreased when combined with Lopinavir.
LopinavirIndapamide may increase the QTc-prolonging activities of Lopinavir.
LornoxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Indapamide.
LovastatinThe metabolism of Indapamide can be decreased when combined with Lovastatin.
LoxoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Loxoprofen.
Lu AA21004Lu AA21004 may increase the hyponatremic activities of Indapamide.
LuliconazoleThe serum concentration of Indapamide can be increased when it is combined with Luliconazole.
LumefantrineIndapamide may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lumiracoxib.
MacitentanIndapamide may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Magnesium salicylate.
ManidipineIndapamide may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Indapamide.
MasoprocolThe therapeutic efficacy of Indapamide can be decreased when used in combination with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Indapamide.
MecamylamineThe risk or severity of adverse effects can be increased when Indapamide is combined with Mecamylamine.
MecamylamineMecamylamine may increase the hypotensive activities of Indapamide.
Meclofenamic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meclofenamic acid.
MedrysoneMedrysone may increase the hypokalemic activities of Indapamide.
Mefenamic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mefenamic acid.
MelengestrolMelengestrol may increase the hypokalemic activities of Indapamide.
MeloxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mesalazine.
MetamizoleThe therapeutic efficacy of Indapamide can be decreased when used in combination with Metamizole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Indapamide.
MethadoneIndapamide may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Indapamide.
MethanthelineThe serum concentration of Indapamide can be increased when it is combined with Methantheline.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Indapamide.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Indapamide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Indapamide.
MethyldopaIndapamide may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Indapamide.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Indapamide.
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Indapamide.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Indapamide.
MetipranololIndapamide may increase the hypotensive activities of Metipranolol.
MetixeneThe serum concentration of Indapamide can be increased when it is combined with Metixene.
MetolazoneMetolazone may increase the hypotensive activities of Indapamide.
MetoprololMetoprolol may increase the hypotensive activities of Indapamide.
MibefradilIndapamide may increase the hypotensive activities of Mibefradil.
MifepristoneThe metabolism of Indapamide can be decreased when combined with Mifepristone.
MifepristoneIndapamide may increase the QTc-prolonging activities of Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Indapamide.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Indapamide.
MilnacipranMilnacipran may increase the hyponatremic activities of Indapamide.
MinaprineMinaprine may increase the hypotensive activities of Indapamide.
MinoxidilMinoxidil may increase the hypotensive activities of Indapamide.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Indapamide.
MitotaneThe serum concentration of Indapamide can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the hypotensive activities of Indapamide.
ModafinilThe serum concentration of Indapamide can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the hypotensive activities of Indapamide.
MolsidomineMolsidomine may increase the hypotensive activities of Indapamide.
MometasoneMometasone may increase the hypokalemic activities of Indapamide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Indapamide.
MoxifloxacinIndapamide may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineIndapamide may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolic acid.
N-butylscopolammonium bromideThe serum concentration of Indapamide can be increased when it is combined with N-butylscopolammonium bromide.
NabumetoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nabumetone.
NadololIndapamide may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Indapamide can be decreased when it is combined with Nafcillin.
NaftifineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Indapamide.
NaproxenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Naproxen.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Indapamide.
NCX 4016The therapeutic efficacy of Indapamide can be decreased when used in combination with NCX 4016.
NebivololIndapamide may increase the hypotensive activities of Nebivolol.
NefazodoneThe metabolism of Indapamide can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Indapamide can be decreased when combined with Nelfinavir.
NepafenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nesiritide.
NetupitantThe serum concentration of Indapamide can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Indapamide can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Indapamide.
NicardipineNicardipine may increase the hypotensive activities of Indapamide.
NicorandilNicorandil may increase the hypotensive activities of Indapamide.
NifedipineThe risk or severity of adverse effects can be increased when Indapamide is combined with Nifedipine.
Niflumic AcidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Niflumic Acid.
NiguldipineIndapamide may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Indapamide can be decreased when combined with Nilotinib.
NilotinibIndapamide may increase the QTc-prolonging activities of Nilotinib.
NilvadipineIndapamide may increase the hypotensive activities of Nilvadipine.
NimesulideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Indapamide.
NisoldipineNisoldipine may increase the hypotensive activities of Indapamide.
NitrendipineIndapamide may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Indapamide.
NitroprussideNitroprusside may increase the hypotensive activities of Indapamide.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Indapamide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Indapamide.
NVA237The serum concentration of Indapamide can be increased when it is combined with NVA237.
ObinutuzumabIndapamide may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Indapamide.
OfloxacinIndapamide may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the hyponatremic activities of Indapamide.
OlaparibThe metabolism of Indapamide can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Indapamide.
OlodaterolOlodaterol may increase the hypokalemic activities of Indapamide.
OlopatadineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olsalazine.
OmapatrilatIndapamide may increase the hypotensive activities of Omapatrilat.
OndansetronIndapamide may increase the QTc-prolonging activities of Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Indapamide.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Indapamide.
OrgoteinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Orgotein.
OrphenadrineThe serum concentration of Indapamide can be increased when it is combined with Orphenadrine.
OsimertinibThe serum concentration of Indapamide can be increased when it is combined with Osimertinib.
OuabainThe risk or severity of adverse effects can be increased when Indapamide is combined with Ouabain.
OxaprozinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxaprozin.
OxcarbazepineThe risk or severity of adverse effects can be increased when Indapamide is combined with Oxcarbazepine.
OxprenololIndapamide may increase the hypotensive activities of Oxprenolol.
OxybutyninThe serum concentration of Indapamide can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Indapamide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Indapamide.
OxyphenbutazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxyphenbutazone.
OxyphenoniumThe serum concentration of Indapamide can be increased when it is combined with Oxyphenonium.
PalbociclibThe serum concentration of Indapamide can be increased when it is combined with Palbociclib.
PaliperidoneIndapamide may increase the QTc-prolonging activities of Paliperidone.
PancuroniumThe serum concentration of Indapamide can be increased when it is combined with Pancuronium.
PanobinostatIndapamide may increase the QTc-prolonging activities of Panobinostat.
PapaverineThe risk or severity of adverse effects can be increased when Indapamide is combined with Papaverine.
ParamethasoneParamethasone may increase the hypokalemic activities of Indapamide.
ParecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Parecoxib.
PargylineIndapamide may increase the hypotensive activities of Pargyline.
ParoxetineParoxetine may increase the hyponatremic activities of Indapamide.
PazopanibIndapamide may increase the QTc-prolonging activities of Pazopanib.
PenbutololIndapamide may increase the hypotensive activities of Penbutolol.
PentamidineIndapamide may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Indapamide.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Indapamide.
PentoliniumIndapamide may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Indapamide.
PerflutrenIndapamide may increase the QTc-prolonging activities of Perflutren.
PerindoprilPerindopril may increase the hypotensive activities of Indapamide.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Indapamide.
PhenelzinePhenelzine may increase the hypotensive activities of Indapamide.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Indapamide.
PheniprazinePheniprazine may increase the hypotensive activities of Indapamide.
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Indapamide.
PhenoxybenzamineIndapamide may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Indapamide.
PhentolaminePhentolamine may increase the hypotensive activities of Indapamide.
PhenylbutazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Phenylbutazone.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Indapamide.
PhenytoinThe metabolism of Indapamide can be increased when combined with Phenytoin.
PimecrolimusThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pimecrolimus.
PimozideIndapamide may increase the QTc-prolonging activities of Pimozide.
PinacidilIndapamide may increase the hypotensive activities of Pinacidil.
PindololIndapamide may increase the hypotensive activities of Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Indapamide.
PipecuroniumThe serum concentration of Indapamide can be increased when it is combined with Pipecuronium.
PirbuterolPirbuterol may increase the hypokalemic activities of Indapamide.
PirenzepineThe serum concentration of Indapamide can be increased when it is combined with Pirenzepine.
PirfenidoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Indapamide.
PiroxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Indapamide.
PolythiazideIndapamide may increase the hypotensive activities of Polythiazide.
PosaconazoleThe metabolism of Indapamide can be decreased when combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Indapamide.
PrazosinPrazosin may increase the hypotensive activities of Indapamide.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Indapamide.
PrednisolonePrednisolone may increase the hypokalemic activities of Indapamide.
PrednisonePrednisone may increase the hypokalemic activities of Indapamide.
PregnenolonePregnenolone may increase the hypokalemic activities of Indapamide.
PrimaquineIndapamide may increase the QTc-prolonging activities of Primaquine.
PrimidonePrimidone may increase the orthostatic hypotensive activities of Indapamide.
ProcainamideIndapamide may increase the QTc-prolonging activities of Procainamide.
ProcaterolProcaterol may increase the hypokalemic activities of Indapamide.
ProcyclidineThe serum concentration of Indapamide can be increased when it is combined with Procyclidine.
PromazineIndapamide may increase the QTc-prolonging activities of Promazine.
PropacetamolThe therapeutic efficacy of Indapamide can be decreased when used in combination with Propacetamol.
PropafenoneIndapamide may increase the QTc-prolonging activities of Propafenone.
PropanthelineThe serum concentration of Indapamide can be increased when it is combined with Propantheline.
PropranololPropranolol may increase the hypotensive activities of Indapamide.
PTC299The therapeutic efficacy of Indapamide can be decreased when used in combination with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Indapamide is combined with Quetiapine.
QuinaprilIndapamide may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Indapamide can be increased when it is combined with Quinidine.
QuinidineIndapamide may increase the QTc-prolonging activities of Quinidine.
QuinineQuinine may increase the hypotensive activities of Indapamide.
QuinineIndapamide may increase the QTc-prolonging activities of Quinine.
RamiprilRamipril may increase the hypotensive activities of Indapamide.
RanolazineThe metabolism of Indapamide can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Indapamide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Indapamide.
RemikirenRemikiren may increase the hypotensive activities of Indapamide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Indapamide.
RescinnamineIndapamide may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Indapamide.
ResveratrolThe therapeutic efficacy of Indapamide can be decreased when used in combination with Resveratrol.
RifabutinThe metabolism of Indapamide can be increased when combined with Rifabutin.
RifampicinThe metabolism of Indapamide can be increased when combined with Rifampicin.
RifapentineThe metabolism of Indapamide can be increased when combined with Rifapentine.
RimexoloneRimexolone may increase the hypokalemic activities of Indapamide.
RiociguatIndapamide may increase the hypotensive activities of Riociguat.
RisperidoneIndapamide may increase the hypotensive activities of Risperidone.
RitodrineRitodrine may increase the hypokalemic activities of Indapamide.
RitonavirThe metabolism of Indapamide can be decreased when combined with Ritonavir.
RituximabIndapamide may increase the hypotensive activities of Rituximab.
RofecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Rofecoxib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Indapamide.
SafrazineSafrazine may increase the hypotensive activities of Indapamide.
SalbutamolSalbutamol may increase the hypokalemic activities of Indapamide.
SalicylamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylic acid.
SalmeterolSalmeterol may increase the hypokalemic activities of Indapamide.
SalsalateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salsalate.
SaprisartanIndapamide may increase the hypotensive activities of Saprisartan.
SaquinavirIndapamide may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Indapamide can be decreased when combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Indapamide.
ScopolamineThe serum concentration of Indapamide can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe serum concentration of Indapamide can be increased when it is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Indapamide.
SelegilineSelegiline may increase the hypotensive activities of Indapamide.
SelexipagIndapamide may increase the hypotensive activities of Selexipag.
SeratrodastThe therapeutic efficacy of Indapamide can be decreased when used in combination with Seratrodast.
SertralineSertraline may increase the hyponatremic activities of Indapamide.
SildenafilSildenafil may increase the antihypertensive activities of Indapamide.
SiltuximabThe serum concentration of Indapamide can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Indapamide can be increased when it is combined with Simeprevir.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Indapamide.
SitaxentanIndapamide may increase the hypotensive activities of Sitaxentan.
SolifenacinThe serum concentration of Indapamide can be increased when it is combined with Solifenacin.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Indapamide.
SpiraprilIndapamide may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Indapamide.
SRT501The therapeutic efficacy of Indapamide can be decreased when used in combination with SRT501.
St. John's WortThe serum concentration of Indapamide can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Indapamide can be increased when it is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide.
SulfasalazineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulfasalazine.
SulfisoxazoleIndapamide may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Indapamide can be decreased when combined with Sulfisoxazole.
SulindacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulindac.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Indapamide.
SulpirideThe risk or severity of adverse effects can be increased when Indapamide is combined with Sulpiride.
SuprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Indapamide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Indapamide.
TelaprevirThe metabolism of Indapamide can be decreased when combined with Telaprevir.
TelavancinIndapamide may increase the QTc-prolonging activities of Telavancin.
TelithromycinIndapamide may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Indapamide can be decreased when combined with Telithromycin.
TelmisartanIndapamide may increase the hypotensive activities of Telmisartan.
TemocaprilIndapamide may increase the hypotensive activities of Temocapril.
TenoxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Indapamide is combined with Terazosin.
TerbutalineTerbutaline may increase the hypokalemic activities of Indapamide.
TeriflunomideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Teriflunomide.
TerlipressinIndapamide may increase the hypotensive activities of Terlipressin.
TetrabenazineIndapamide may increase the QTc-prolonging activities of Tetrabenazine.
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Indapamide.
ThiopentalThiopental may increase the orthostatic hypotensive activities of Indapamide.
ThioridazineIndapamide may increase the QTc-prolonging activities of Thioridazine.
Tiaprofenic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tiaprofenic acid.
TiboloneIndapamide may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Indapamide can be decreased when combined with Ticlopidine.
TicrynafenIndapamide may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Indapamide.
TiotropiumThe serum concentration of Indapamide can be increased when it is combined with Tiotropium.
TixocortolTixocortol may increase the hypokalemic activities of Indapamide.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Indapamide.
TocilizumabThe serum concentration of Indapamide can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Indapamide.
TolazolineTolazoline may increase the hypotensive activities of Indapamide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Indapamide.
Tolfenamic AcidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Indapamide.
TolterodineThe serum concentration of Indapamide can be increased when it is combined with Tolterodine.
TopiramateIndapamide may increase the hypokalemic activities of Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Indapamide.
ToremifeneIndapamide may increase the hypercalcemic activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Indapamide.
TrandolaprilTrandolapril may increase the hypotensive activities of Indapamide.
TranilastThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Indapamide.
TranylcypromineTranylcypromine may increase the hypotensive activities of Indapamide.
TravoprostTravoprost may increase the hypotensive activities of Indapamide.
TrazodoneTrazodone may increase the hyponatremic activities of Indapamide.
TreprostinilTreprostinil may increase the hypotensive activities of Indapamide.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Indapamide.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Indapamide.
TrichlormethiazideIndapamide may increase the hypotensive activities of Trichlormethiazide.
TrihexyphenidylThe serum concentration of Indapamide can be increased when it is combined with Trihexyphenidyl.
TrimazosinIndapamide may increase the hypotensive activities of Trimazosin.
TrimethaphanIndapamide may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Trisalicylate-choline.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Indapamide.
TropicamideThe serum concentration of Indapamide can be increased when it is combined with Tropicamide.
TrospiumThe serum concentration of Indapamide can be increased when it is combined with Trospium.
TubocurarineThe serum concentration of Indapamide can be increased when it is combined with Tubocurarine.
UdenafilUdenafil may increase the antihypertensive activities of Indapamide.
UmeclidiniumThe serum concentration of Indapamide can be increased when it is combined with Umeclidinium.
UnoprostoneIndapamide may increase the hypotensive activities of Unoprostone.
ValdecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Indapamide.
VandetanibIndapamide may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the antihypertensive activities of Indapamide.
VecuroniumThe serum concentration of Indapamide can be increased when it is combined with Vecuronium.
VemurafenibIndapamide may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Indapamide can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Indapamide.
VilanterolVilanterol may increase the hypokalemic activities of Indapamide.
VilazodoneVilazodone may increase the hyponatremic activities of Indapamide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Indapamide.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Indapamide.
VoriconazoleThe metabolism of Indapamide can be decreased when combined with Voriconazole.
VortioxetineVortioxetine may increase the hyponatremic activities of Indapamide.
XylometazolineIndapamide may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Indapamide.
ZaltoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zileuton.
ZimelidineZimelidine may increase the hyponatremic activities of Indapamide.
ZiprasidoneThe metabolism of Indapamide can be decreased when combined with Ziprasidone.
ZiprasidoneIndapamide may increase the QTc-prolonging activities of Ziprasidone.
ZomepiracThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zomepirac.
ZuclopenthixolIndapamide may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Magnesium, potassium and zinc needs increased.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modulates current kinetics (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505, PubMed:19687231). Induces a voltage-dependent by rapidly activating and slowly ...
Gene Name:
KCNQ1
Uniprot ID:
P51787
Molecular Weight:
74697.925 Da
References
  1. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y: Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G277-87. [PubMed:11804849 ]
  2. Li RA, Miake J, Hoppe UC, Johns DC, Marban E, Nuss HB: Functional consequences of the arrhythmogenic G306R KvLQT1 K+ channel mutant probed by viral gene transfer in cardiomyocytes. J Physiol. 2001 May 15;533(Pt 1):127-33. [PubMed:11351021 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Telethonin binding
Specific Function:
Ancillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel complex. Assembled with KCNB1 modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 (PubMed:19219384). Assembled with KCNQ1/KVLQT1 is proposed to for...
Gene Name:
KCNE1
Uniprot ID:
P15382
Molecular Weight:
14674.66 Da
References
  1. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y: Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G277-87. [PubMed:11804849 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Sun H, Moore C, Dansette PM, Kumar S, Halpert JR, Yost GS: Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos. 2009 Mar;37(3):672-84. doi: 10.1124/dmd.108.022707. Epub 2008 Dec 12. [PubMed:19074530 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23